RT Journal Article
SR Electronic
T1 Pandemic impacts on healthcare utilisation: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.26.20219352
DO 10.1101/2020.10.26.20219352
A1 Moynihan, Ray
A1 Sanders, Sharon
A1 Michaleff, Zoe A
A1 Scott, Anna
A1 Clark, Justin
A1 To, Emma J
A1 Jones, Mark
A1 Kitchener, Eliza
A1 Fox, Melissa
A1 Johansson, Minna
A1 Lang, Eddy
A1 Duggan, Anne
A1 Scott, Ian
A1 Albarqouni, Loai
YR 2020
UL http://medrxiv.org/content/early/2020/10/28/2020.10.26.20219352.abstract
AB Objectives To determine the extent and nature of changes in utilisation of healthcare services during COVID-19 pandemic.Design Systematic reviewEligibility Eligible studies compared utilisation of services during COVID-19 pandemic to at least one comparable period in prior years. Services included visits, admissions, diagnostics, and therapeutics. Studies were excluded if from single-centres or studied only COVID-19 patients.Data sources PubMed, Embase, Cochrane COVID-19 Study Register, and pre-prints were searched, without language restrictions, until August 10, using detailed searches with key concepts including COVID-19, health services and impact.Data analysis Risk of bias was assessed by adapting ROBINS-I and Cochrane Effective Practice and Organization of Care tool. Results were analysed using descriptive statistics, graphical figures, and narrative synthesis.Outcome measures Primary outcome was change in service utilisation between pre-pandemic and pandemic periods. Secondary outcome was the change in proportions of users of healthcare services with milder or more severe illness (e.g. triage scores).Results 3097 unique references were identified, and 81 studies across 20 countries included, reporting on >11 million services pre-pandemic and 6.9 million during pandemic. For the primary outcome, there were 143 estimates of changes, with a median 37% reduction in services overall (interquartile range −51% to −20%), comprising median reductions for visits of 42%(−53% to −32%), admissions, 28%(−40% to −17%), diagnostics, 31%(−53% to −24%), and for therapeutics, 30%(−57% to −19%). Among 35 studies reporting secondary outcomes, there were 60 estimates, with 27(45%) reporting larger reductions in utilisation among people with a milder spectrum of illness, and 33 (55%) reporting no change.Conclusions Healthcare utilisation decreased by about a third during the pandemic, with considerable variation, and with greater reductions among people with less severe illness. While addressing unmet need remains a priority, studies of health impacts of reductions may help health-systems prioritise higher-value care in the post-pandemic recovery.Funding, Study registration No funding was required. PROSPERO: CRD42020203729Strengths and limitations of this study– The review is the first broad synthesis of global studies of pandemic related changes in utilisation across all categories of healthcare services.– The review provides novel findings informing design of future studies of pandemic-related changes in utilisation and its impacts.– Limitations include the possibility of publication bias and the potential of our eligibility criteria to exclude important data sources such as studies in single-centres and unpublished datasets from health systems.– Heterogenous designs and settings precluding meta-analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was required for this study. The lead author RM is funded by an Australian National Health and Medical Research Council, NHMRC fellowship grant No 1124207 and is a chief investigator on an NHMRC Centre for Research Excellence, grant No 1104136. We confirm all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. Authors write as individuals, not as representatives of organisations with which they work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided all data about all included studies, and a list of those studies, in the Supplementary files.